The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1096
January 22, 2001
View Complete Issue         Table of Contents 2019 
Fluoxetine Sarafem For Premenstrual Dysphoric Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Fluoxetine Sarafem For Premenstrual Dysphoric Disorder
January 22, 2001 (Issue: 1096)
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) previously sold only as Prozac, is now also marketed as Sarafem for treatment of premenstrual dysphoric disorder (PMDD). Generic fluoxetine is expected to be available sometime this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Fluoxetine Sarafem For Premenstrual Dysphoric Disorder
Article code: 1096a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.